Camibirstat

Camibirstat
Clinical data
Other names	FHD286
Identifiers
	IUPAC name N-[(2S)-1-[[4-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl]-1,3-thiazol-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonylpyrrole-3-carboxamide;
CAS Number	2671128-05-3;
PubChem CID	156818030;
ChemSpider	115010237;
UNII	QHA5XLA4SA;
ChEMBL	ChEMBL5095181;
Chemical and physical data
Formula	C24H30N6O6S2
Molar mass	562.66 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CN(C[C@@H](O1)C)C2=CC=CC(=N2)C3=CSC(=N3)NC(=O)[C@H](COC)NC(=O)C4=CN(C=C4)S(=O)(=O)C;
	InChI InChI=InChI=1S/C24H30N6O6S2/c1-15-10-29(11-16(2)36-15)21-7-5-6-18(25-21)20-14-37-24(27-20)28-23(32)19(13-35-3)26-22(31)17-8-9-30(12-17)38(4,33)34/h5-9,12,14-16,19H,10-11,13H2,1-4H3,(H,26,31)(H,27,28,32)/t15-,16+,19-/m0/s1; Key:JBLQNFBXKOAIHG-FCEWJHQRSA-N;

Camibirstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small molecule that acts as a selective inhibitor of SMARCA2 and SMARCA4, which are key components of the SWI/SNF chromatin remodeling complex.^[1]

It is being developed by Foghorn Therapeutics.^[2]

References

↑ Yu L, Wu D (July 2024). "SMARCA2 and SMARCA4 Participate in DNA Damage Repair". Frontiers in Bioscience (Landmark Edition). 29 (7): 262. doi:10.31083/j.fbl2907262. PMID 39082357.
↑ "Camibirstat". PatSnap.

[Yu_2024-1] Yu L, Wu D (July 2024). "SMARCA2 and SMARCA4 Participate in DNA Damage Repair". Frontiers in Bioscience (Landmark Edition). 29 (7): 262. doi:10.31083/j.fbl2907262. PMID 39082357.

[2] "Camibirstat". PatSnap.

[1]

[2]